new injectible product could be the best in portfolio IMO..the reason is the biologics segment is almost all injectible (or infusion), and not a pill or tablet business, and hospital based... but now that "bio-similars" (like generic bilogics) are just starting to come out, RX is in a perfect position , to go after this ...projections are biosimilars will grow from 1 B to 30 Billion over next 4 or 5 years in NA... and CAGR therafter in high teens... The Pfizor deal last week for Hospira was for this market...